ReviewEuropean radiology2020
Gadoxetic acid-enhanced MR imaging for hepatocellular carcinoma: molecular and genetic background.
Review in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 62 citations in OpenAlex.
- Beyond Diagnosis: Magnetic Resonance Imaging-Based Imaging Biomarkers for Tumor Biology, Prognosis, and Clinical Decision-Making in Hepatocellular Carcinoma.Korean journal of radiology · 2026Review
- SLC Transporter-Mediated Functional Imaging in Cancer Diagnosis.Biomolecules · 2026Review
- Diagnostic Performance and Clinical Implications of the "Probable Hepatocellular Carcinoma" Category in the Korean Liver Cancer Association-National Cancer Center Korea Guidelines v2022.Korean journal of radiology · 2026Article
- Imaging for molecular and pathological subtyping of hepatocellular carcinoma-a critical appraisal and future directions.European radiology · 2026Review
- [Expert consensus on overall standardized management of gadoxetate disodium-enhanced MRI examinations (version 2026)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Noninvasive Prediction of High Ki-67 Expression in Hepatocellular Carcinoma Using Multiparametric MRI and Clinical Biomarkers.Journal of hepatocellular carcinoma · 2026Article
- Deep learning-based MRI model for predicting P53-mutated hepatocellular carcinoma.BMC medical imaging · 2025Article
- Prediction of Histopathological Grade of Hepatocellular Carcinoma by Gadoxetic Acid-Enhanced Magnetic Resonance Imaging Radiomics Features.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Comparison of Apparent Diffusion Coefficient Values on Diffusion-Weighted MRI for Differentiating Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.Diagnostics (Basel, Switzerland) · 2025Article
- Super delayed phase imaging in gadoxetic acid-enhanced MRI: investigating factors contributing to improved liver contrast.European radiology · 2025Article
- MRI Imaging Biomarkers for Prognostication of Hepatocellular Carcinoma.Journal of the Korean Society of Radiology · 2025Review
- Habitat radiomics and deep learning on gadoxetic acid-enhanced MRI for noninvasive assessment of CK19 expression and recurrence-free survival in hepatocellular carcinoma.Frontiers in oncology · 2025Article
- A controlled study of Gd-EOB-DTPA-enhanced MRI compared with enhanced CT in assessing lesion status after TACE for hepatocellular carcinoma.Frontiers in medicine · 2025Article
- [Hepatobiliary phase image manifestation classification and pathological features of nodules in nodules accompanied by hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Nodule-in-nodule architecture of hepatocellular carcinomas: enhancement patterns in the hepatobiliary phase and pathological features.Abdominal radiology (New York) · 2024Article
- Clear cell hepatocellular carcinoma: Gd-EOB-DTPA-enhanced MR imaging features and prognosis.Abdominal radiology (New York) · 2024Article
- Diagnostic algorithm for subcentimeter hepatocellular carcinoma using alpha-fetoprotein and imaging features on gadoxetic acid-enhanced MRI.European radiology · 2024Article
- Hepatobiliary-phase gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid MRI for pretreatment prediction of efficacy-to-standard-therapies based on Barcelona Clinic Liver Cancer algorithm: an up-to-date review.European radiology · 2023Review
- Current Status of Cancer Genomics and Imaging Phenotypes: What Radiologists Need to Know.Radiology. Imaging cancer · 2023Review
- Prognosis Prediction of Hepatocellular Carcinoma Based on Magnetic Resonance Imaging Features.Korean journal of radiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gadoxetic acid-enhanced magnetic resonance imaging (MRI) plays important roles in diagnosis of hepatic lesions because of its superiority in the detectability of small lesions, its differentiation ability, and its utility for the early diagnosis of hepatocellular carcinoma (HCC). In HCC, expression of organic anion transporting polypeptide (OATP) 1B3 correlates with the enhancement ratio in the hepatobiliary phase. Gadoxetic acid-enhanced MRI, an indirect molecular imaging method, reflects OATP1B3 expression in HCC. OATP1B3 expression gradually decreases from the dysplastic nodule stage to advanced HCC. Decreased expression is a sensitive marker of multistep hepatocarcinogenesis, especially in the early stages. Hypervascular HCCs commonly show hypointensity in the hepatobiliary phase corresponding to a decrease in OATP1B3; however, approximately 10% of HCCs show hyperintensity due to OATP1B3 overexpression. This hyperintense HCC shows less aggressive biological features and has a better prognosis than hypointense HCC. Hyperintense HCC can be classified into a genetic subtype of HCC with a mature hepatocyte-like molecular expression. OATP1B3 expression and the less aggressive nature of hyperintense HCC are regulated by the molecular interaction of β-catenin signaling and hepatocyte nuclear factor 4α, a tumor suppressor factor. Gadoxetic acid-enhanced MR imaging has the potential to be an imaging biomarker for HCC. KEY POINTS: • The hepatobiliary phase is a sensitive indirect indicator of organic anion transporting polypeptide1B3 (OATP1B3) expression in hepatocellular carcinoma (HCC). • The OATP1B3 expression, namely, enhancement in the hepatobiliary phase, decreases from the very early stage of hepatocarcinogenesis, contributing to early diagnosis of HCC. • HCC showing hyperintensity on the hepatobiliary phase is a peculiar genetic subtype of HCC with OATP1B3 overexpression, a less aggressive nature, and mature hepatocyte-like molecular/genetic features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.